COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
06/08/2026
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed [...]
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
06/08/2026
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study builds on [...]
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
06/08/2026
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to [...]
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
06/08/2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial design to characterize [...]
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
06/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to [...]
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast [...]
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
06/08/2026
ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable [...]
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
06/08/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; [...]
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
06/08/2026
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc [...]
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
06/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
06/08/2026
Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1 Phase 1b [...]
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
06/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world [...]
Spirited Paw® Healthy Mind By Standard Process® Named 2026 Senior Dog Nutrition Product of the Year
06/08/2026
The award recognizes Standard Process’ science-informed, whole food-based approach to supporting cognitive health in senior dogs PALMYRA, Wis., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Standard Process ® , a leader in whole [...]
Sonablate Announces Landmark Global Strategic Alliance with Eleven Ventures to Advance AI-Powered Precision Medicine
06/08/2026
Agreement establishes long-term commitment to support global expansion of Sonablate’s therapeutic ultrasound technology and facilitate up to $200 million in strategic capital formation JEDDAH, Saudi Arabia and CHARLOTTE [...]
Philips expands open patient monitoring ecosystem to help health systems keep sight of patients beyond the bedside
06/08/2026
August 6, 2026 New collaborations expand wearable and out-of-hospital monitoring capabilities, helping support continuous patient visibility from admission through recovery at home Amsterdam, Netherlands. – Royal [...]
Alpha Pro Tech, Ltd. Announces Second Quarter 2026 Financial Results
06/08/2026
Second Quarter Net Sales Increased by 12% to $18.7 Million from $16.7 Million in the Second Quarter of 2025; Second Quarter Net Income Increased by 47% to $1.8 Million from $1.2 Million in the Prior Year Period Net [...]
Kyntra Bio to Report Second Quarter 2026 Financial Results
06/08/2026
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference [...]

Pages